After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
BMN 270 is one of the most important drugs in Biomarin's research pipeline and key driver of future revenue and earnings.
The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.
TheStreet highlights 3 stocks pushing the drugs industry higher today.
All of these add up to a level of insecurity on the part of sidelined money.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.